Navigation Links
Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease
Date:7/7/2008

25-4860 internationally. A telephone replay will be available following the conclusion of the call until July 9 at midnight by dialing 888-203-1112 from the U.S. or 719-457-0820 for international callers and entering passcode 4109873. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to improve the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon(TM) in Alzheimer's disease, a Phase 2 clinical trial of Dimebon in patients with Huntington's disease, and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding anticipated future development of Dimebon, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candida
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... (Nasdaq: STXS ) announced today that the underwriters for ... exercised in full their over-allotment option to purchase an additional ... shares of Stereotaxis common stock in the offering, including the ... at a price to the public of $4.00 per share. ...
... Held in the heart of Brasil,s pharmaceutical industry, Sao ... pharma ingredients and production technology events built strongly on their ... numbers for the 150+ exhibitors at the Transamerica Expo Center ... Rio, with a major international presence. Organisers UBM International ...
Cached Medicine Technology:Stereotaxis Announces Underwriters' Exercise of Over-Allotment Option 2Stereotaxis Announces Underwriters' Exercise of Over-Allotment Option 3Sao Paulo Hosts Strong Second Year for South American Pharma Events 2
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to announce ... Services at North Carolina State’s College of Veterinary Medicine ... Award for Distinguished Volunteer Service—the organization’s highest award. ... of volunteer experts to direct its work to improve ...
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been ... business is showing its latest designs of wedding dresses and ... the company’s CEO, all the fresh new products are designed ... up to 80% off. All the clothes from LunaDress follow ...
(Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
(Date:1/22/2015)... Glendale, AZ (PRWEB) January 22, 2015 Padre ... a long supporter of Pro Player Health Alliance ... with Padre Murphy's in getting everyone, including NFL greats, treated ... one of the leading groups supporting the cause in the ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2
... Health Inc, (TSX:,DAX) (NASDAQ: DRAX ) has received ... announced Normal Course Issuer Bid (NCIB) to,purchase up to ... common shares in the public float as at January ... of DRAXIS were issued and,outstanding., Purchases may begin ...
... Pharmacies to Negotiate Collectively Would,Increase Costs by Only ... 16 Despite pharmacy benefit,managers, (PBMs) claims that ... with PBMs, would increase costs to,Medicare D and ... Office (CBO) rejected this bogus number., This ...
... Ross J. Horsburgh Brings 20 Years of Pharmaceutical and CRO ... in Asia/Pacific Region to Key Leadership Role, ... a,leading, global full-service clinical research organization (CRO), today,announced Dr. Ross ... Development - Asia/Pacific. In this role, he will lead the,company,s ...
... It,s often hard for,children on the autism ... friendship and play time as much as any ... help ASD children foster friendships at a,Pittsburgh-area conference ... Learning Center LLC, the conference will feature,author-founder-parent Heather ...
... carcinoma (HCC) patients in China may be treated with ... doubt its effectiveness. These stated that a research group ... of PTEN in HCC, which may suppress tumor cell ... A research article published on January 7, 2008 ...
... 16, 2008 A procedure called carotid artery stenting ... surgery, called carotid endarterectomy (CEA), for patients with dangerous ... However, questions remain about the best uses of ... surgery for "low-risk" patients, according to a special article ...
Cached Medicine News:Health News:DRAXIS Share Buyback Approved by TSX 2Health News:DRAXIS Share Buyback Approved by TSX 3Health News:DRAXIS Share Buyback Approved by TSX 4Health News:Congressional Budget Office Analysis of HR971 Rejects Pharmacy Benefit Managers' Bogus Claim Bill Would Cost $29 Billion Over 5 Years 2Health News:Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion 2Health News:Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion 3Health News:PA Cyber Sponsors Conference on Helping Children With Autism Form Friendships 2Health News:How does Fu-Zheng-Jie-Du-Decoction act on PTEN expression in hepatocellular carcinoma? 2Health News:Vascular surgeons ask, what's next for carotid artery stenting? 2
Spanish reading test....
... Flip charts contain 5 pages of various contrast ... Optotype size is 9.5M. Contrast levels are 25%, ... can be used at several different distances. These ... Each offers a different set of symbols ...
Near PT test card/Tumbling E, tumbling hands 5 1/2" X 8"....
... The PowerLab 2/25 is an economically ... for teaching and research use in ... physiology, pharmacology, neurophysiology, biology, zoology, biochemistry ... supports all ADInstruments signal conditioners and ...
Medicine Products: